Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia. (October 2021)

• Record Type: Journal Article
• Authors: Kallel, Faten; Kassar, Olfa; Maaloul, Imen; Charfi, Maha; Ksouda, Kamilia; Elloumi, Moez
• Is Part Of: Journal of oncology pharmacy practice. Volume 27:Number 7(2021)
• Page Start: 1762
• Page End: 1765
• Publication Date: 2021-10
• Subjects: Imatinib -- pulmonary toxicity -- chronic myeloid leukemia -- pneumonitis; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220984239
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Pulmonary toxicity causally related to Imatinib (IM) therapy is uncommon in patients with chronic myeloid leukemia. Case report: A 61-year-old patient with chronic myeloid leukemia was treated with IM at 400 mg daily dose. One month within IM, he developed skin lesions and then acute dyspnea and non-productive cough. Chest radiograph and high-resolution lung computed tomography (CT) revealed bilateral reticulonodular infiltration in both lungs. According to Naranjo's algorithm, the causality relationship with the drug is probable with a score of 7. The pharmacovigilance investigation was carried out and implicated IM Management & outcome: IM was discontinued and started steroid therapy (Prednisolone®) at 1 mg/kg daily. Two weeks after, the dyspnea, and abnormal X-ray and CT findings are improved. Discussion: The early diagnosis of pulmonary toxicity related to IM therapy is needed to avoid further determinal effects of the drug.